Market For Telemedicine And RPM Expanding, Says GlobalData

New Delhi (IANS) The market for telemedicine and remote patient monitoring (RPM) has been rapidly expanding, driven by the Covid-19 pandemic and the need for remote healthcare delivery, according to a report on Monday.

The report by GlobalData, a data and analytics company, stated that RPM devices are estimated to grow to a market value of $1.2 billion by 2025, while the market for telemedicine is projected to reach $185.6 billion by 2026.

RPM devices allow healthcare providers to monitor patients’ health metrics from a distance.

This technology provides early detection of health problems and can prevent unnecessary hospital visits, making it an attractive option for both patients and providers.

“Artificial Intelligence (AI) is also being integrated into telemedicine and RPM, enabling providers to analyse data from remote monitoring devices and gain valuable insights into patient health,” said Cynthia Stinchcombe, Medical Devices Analyst at GlobalData, in a statement.

Stinchcombe noted that the technology also has the potential to significantly improve patient outcomes as well as reduce healthcare costs.

In addition to these developments, telemedicine is also becoming more accessible to patients.

Virtual consultations allow patients to connect with their healthcare providers from anywhere, and market growth is being driven by the convenience and cost-effectiveness of virtual visits as well as the availability of high-speed internet and mobile devices.

“The expansion of telemedicine and RPM is expected to continue in the coming years, as these technologies become increasingly vital to the healthcare industry,” Stinchcombe said.

“With the ongoing Covid-19 pandemic and the growing demand for virtual healthcare, telemedicine and RPM are poised to play a critical role in delivering healthcare services to patients around the world,” she added.

  • Related Posts

    NPPA Revises Retail and Ceiling Prices of 35 Drug Formulations; Fixes Prices of 34 New Drugs, Cholecalciferol, Oxaliplatin and Sun Pharma’s Diclofenac Gel

    New Delhi: The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, has issued four price-related notifications dated November 2, 2026, covering the fixation…

    ED attaches assets, freezes bank account in counterfeit medicines racket; searches five premises in Bengaluru

    During the raid, the accused were allegedly found storing medicines and pharmaceutical drugs without valid licences, permits or authorisations and replacing labels on the stored medicines. The Directorate of Enforcement…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    NPPA Revises Retail and Ceiling Prices of 35 Drug Formulations; Fixes Prices of 34 New Drugs, Cholecalciferol, Oxaliplatin and Sun Pharma’s Diclofenac Gel

    NPPA Revises Retail and Ceiling Prices of 35 Drug Formulations; Fixes Prices of 34 New Drugs, Cholecalciferol, Oxaliplatin and Sun Pharma’s Diclofenac Gel

    ED attaches assets, freezes bank account in counterfeit medicines racket; searches five premises in Bengaluru

    ED attaches assets, freezes bank account in counterfeit medicines racket; searches five premises in Bengaluru

    Hyderabad Startup Working On Personalised Cancer Vaccine: What It Means For Cancer Treatment

    Hyderabad Startup Working On Personalised Cancer Vaccine: What It Means For Cancer Treatment

    Medicines that cure Us are making Our Environment Sick

    Medicines that cure Us are making Our Environment Sick

    ZEN- G packs a punch in Organ Donation as Over 500 Students pledge Organs

    ZEN- G packs a punch in Organ Donation as Over 500 Students pledge Organs

    PGIMS recalls drug amid probe into deaths

    PGIMS recalls drug amid probe into deaths